Key facts
- This page summarizes Gerald M. Lieberman's Form 4 filing for Entera Bio Ltd. (ENTX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Jan 2026, 16:21.
Gerald M. Lieberman - 01 Jan 2026 Form 4 Insider Report for Entera Bio Ltd. (ENTX)
- Reporting relationship
- Director
- Issuer ticker
- ENTX
- Reported as of
- 01 Jan 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Jan 2026, 16:21:15 UTC
- Prior SEC filing
- 09 Jun 2025
- Next SEC filing
- 01 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dana Yaacov-Garbeli, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Gerald M. Lieberman filed Form 4 for Entera Bio Ltd. (ENTX) on 02 Jan 2026.
Change
- Previous filing in this sequence was filed on 09 Jun 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001234346
Primary reporting owner
LIEBERMAN GERALD M
- Relationship
- Director
- Address
- KIRYAT HADASSAH, MINRAV BUILDING, 5TH FLOOR, JERUSALEM, ISRAEL
- Signature
- /s/ Dana Yaacov-Garbeli, Attorney-in-Fact
- Signature date
- 02 Jan 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ENTX
transaction
Ordinary Shares, par value NIS 0.0000769 per share
Award
- Transaction value
- $0
- Shares
- +38,294
- Change %
- +13%
- Price
- $0.000000
- Shares after
- 338,454
- Date
- 01 Jan 2026
- Ownership
- Direct
- Footnotes
- F1
ENTX
holding
Ordinary Shares, par value NIS 0.0000769 per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,200
- Date
- 01 Jan 2026
- Ownership
- By Trust
- Footnotes
- F2
ENTX
holding
Ordinary Shares, par value NIS 0.0000769 per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,200
- Date
- 01 Jan 2026
- Ownership
- By Trust
- Footnotes
- F2
ENTX
holding
Ordinary Shares, par value NIS 0.0000769 per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,200
- Date
- 01 Jan 2026
- Ownership
- By Trust
- Footnotes
- F2
ENTX
holding
Ordinary Shares, par value NIS 0.0000769 per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,200
- Date
- 01 Jan 2026
- Ownership
- By Trust
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ENTX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +33,505
- Change %
- Price
- $0.000000
- Shares after
- 33,505
- Date
- 01 Jan 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares, par value NIS 0.0000769 per share
- Underlying amount
- 33,505
- Exercise price
- $1.94
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the 2025 fiscal year.
Footnote F2
These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Footnote F3
These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2026.